Provectus News Provectus Biopharmaceuticals Ex
Post# of 22759
Posted On: 11/14/2014 8:04:39 AM
Provectus News
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
Thursday November 13, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI", the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK", the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.
During the last 90 days, since the signing of the MOU, management of Provectus and senior personnel at Sinopharm-CSIPI and Sinopharm A-THINK have held numerous conference calls, have met face-to-face in both China and the US, and Chinese scientists on staff at Sinopharm have discussed in person PV-10 and its clinical results with the lead investigators at St. Luke's Cancer Center and Moffitt Cancer Center.
Dr. Zhidan Jia, Chief Executive Officer of Sinopharm A-THINK, echoed these sentiments saying, "I am happy with the progress we made so far as our relationship with PVCT moves forward. Sinopharm will do more research on the recent filed PV-10 Phase 3 trial protocol. It will allow us to understand the drug better, and will help both parties to move forward in the Chinese market."
The Company stated that it is hopeful that a contract will be finalized in the coming weeks, and this extension illustrates that there is sufficient interest on both sides to continue to work out the details. With the new data from the Moffitt Cancer Center on combination therapy with IL PV-10 and co-inhibitory blockade, and considering Provectus' filing of the phase 3 protocol with the FDA in Washington, both parties agreed to take the additional time needed to ensure that the final contract is the best agreement possible for everyone.
The MOU will now terminate upon the signature of a licensing agreement or other contract, on May 16, 2015, or with one-month written notice by either party.
The complete press release is available at www.pvct.com/pressrelease.html?article=20141114 on the Provectus website.
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
Thursday November 13, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI", the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK", the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term. During the last 90 days, since the signing of the MOU, management of Provectus and senior personnel at Sinopharm-CSIPI and Sinopharm A-THINK have held numerous conference calls, have met face-to-face in both China and the US, and Chinese scientists on staff at Sinopharm have discussed in person PV-10 and its clinical results with the lead investigators at St. Luke's Cancer Center and Moffitt Cancer Center.
Dr. Zhidan Jia, Chief Executive Officer of Sinopharm A-THINK, echoed these sentiments saying, "I am happy with the progress we made so far as our relationship with PVCT moves forward. Sinopharm will do more research on the recent filed PV-10 Phase 3 trial protocol. It will allow us to understand the drug better, and will help both parties to move forward in the Chinese market."
The Company stated that it is hopeful that a contract will be finalized in the coming weeks, and this extension illustrates that there is sufficient interest on both sides to continue to work out the details. With the new data from the Moffitt Cancer Center on combination therapy with IL PV-10 and co-inhibitory blockade, and considering Provectus' filing of the phase 3 protocol with the FDA in Washington, both parties agreed to take the additional time needed to ensure that the final contract is the best agreement possible for everyone.
The MOU will now terminate upon the signature of a licensing agreement or other contract, on May 16, 2015, or with one-month written notice by either party.
The complete press release is available at www.pvct.com/pressrelease.html?article=20141114 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼